Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer

Overview

Journal J Gastric Cancer

Date 2016 Jul 20

PMID 27433393

Citations 11

Authors

Si-Hyong Jang

Kyung-Ju Kim

Mee-Hye Oh

Ji-Hye Lee

Hyun Ju Lee

Hyun Deuk Cho

Sun Wook Han

Myoung Won Son

Moon Soo Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: PIK3CA is often mutated in a variety of malignancies, including colon, gastric, ovary, breast, and brain tumors. We investigated PIK3CA expression in gastric cancer and explored the relationships between the PIK3CA expression level and clinicopathological features as well as survival of the patients.

Materials And Methods: We examined PIK3CA expression in a tissue microarray of 178 gastric adenocarcinomas by immunohisto-chemistry and reviewed patients' medical records.

Results: In our study, 112 of the 178 gastric cancer patients displayed positive PIK3CA expression. Overexpression of PIK3CA was correlated with low grade differentiation (P=0.001), frequent lymphatic invasion (P=0.032), and high T stage (P=0.040). Patients with positive PIK3CA staining were more likely to display worse overall survival rate than those with negative PIK3CA staining, as determined by Kaplan-Meier survival analysis with log-rank test (P=0.047) and a univariate analysis using the Cox proportional hazard model (hazard ratio=1.832, P=0.051).

Conclusions: Elevated PIK3CA expression was significantly correlated with tumor invasiveness, tumor phenotypes, and poor patient survival.

Citing Articles

Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.

Lenis A, Whiting K, Ravichandran V, Tallman J, Alam S, Chu C JCO Precis Oncol. 2024; 8:e2300274.

PMID: 38691813 PMC: 11310921. DOI: 10.1200/PO.23.00274.

The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape.

Salnikov M, MacNeil K, Mymryk J Front Immunol. 2024; 15:1358511.

PMID: 38596668 PMC: 11002251. DOI: 10.3389/fimmu.2024.1358511.

Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor.

Kim S, Seung B, Cho S, Lim H, Bae M, Sur J Animals (Basel). 2021; 11(7).

PMID: 34359206 PMC: 8300234. DOI: 10.3390/ani11072079.

Identification and Validation of SNP-Containing Genes With Prognostic Value in Gastric Cancer Integrated Bioinformatics Analysis.

Li H, Guo J, Cheng G, Wei Y, Liu S, Qi Y Front Oncol. 2021; 11:564296.

PMID: 33987081 PMC: 8112818. DOI: 10.3389/fonc.2021.564296.

Genetic profiling of somatic alterations by Oncomine Focus Assay in Korean patients with advanced gastric cancer.

Park J, Lee S, Shin S, Hong J, Yoo H, Kim J Oncol Lett. 2020; 20(5):129.

PMID: 32934698 PMC: 7471730. DOI: 10.3892/ol.2020.11990.

References

Li V, Wong C, Chan T, Chan A, Zhao W, Chu K . Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 2005; 5:29. PMC: 1079799. DOI: 10.1186/1471-2407-5-29. View

Zhou X, Tang S, Yi G, Hou M, Chen J, Yang B . RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells. World J Gastroenterol. 2011; 17(32):3700-8. PMC: 3181455. DOI: 10.3748/wjg.v17.i32.3700. View

Chen Y, Hou Q, Yan W, Luo J, Chen D, Liu Z . PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells. Oncol Res. 2012; 19(12):563-71. DOI: 10.3727/096504012x13340632812677. View

Levine D, Bogomolniy F, Yee C, Lash A, Barakat R, Borgen P . Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005; 11(8):2875-8. DOI: 10.1158/1078-0432.CCR-04-2142. View

Kim K, Lee K, Cho H, Kim Y, Yang H, Kim W . Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers. Hum Pathol. 2013; 45(2):285-93. DOI: 10.1016/j.humpath.2013.09.004. View

Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M . Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer. 2008; 16(1):301-10. DOI: 10.1677/ERC-08-0167. View

Engelman J, Luo J, Cantley L . The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-19. DOI: 10.1038/nrg1879. View

Ibarrola-Villava M, Llorca-Cardenosa M, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo J . Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer. Oncotarget. 2015; 6(29):26935-45. PMC: 4694964. DOI: 10.18632/oncotarget.4775. View

Liu X, Cai H, Sheng W, Yu L, Long Z, Shi Y . Clinicopathological Characteristics and Survival Outcomes of Primary Signet Ring Cell Carcinoma in the Stomach: Retrospective Analysis of Single Center Database. PLoS One. 2015; 10(12):e0144420. PMC: 4671648. DOI: 10.1371/journal.pone.0144420. View

10.

Wen F, He S, Sun C, Li T, Wu S . PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. Int J Clin Exp Pathol. 2015; 7(11):8295-303. PMC: 4270546. View

11.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

12.

LAUREN P . THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965; 64:31-49. DOI: 10.1111/apm.1965.64.1.31. View

13.

Liu J, Zhou X, Chen J, Yi G, Chen H, Ba M . Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J Gastroenterol. 2010; 16(39):4986-91. PMC: 2957609. DOI: 10.3748/wjg.v16.i39.4986. View

14.

Sukawa Y, Yamamoto H, Nosho K, Ito M, Igarashi H, Naito T . HER2 expression and PI3K-Akt pathway alterations in gastric cancer. Digestion. 2014; 89(1):12-7. DOI: 10.1159/000356201. View

15.

Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G . Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer. 2012; 12:50. PMC: 3299648. DOI: 10.1186/1471-2407-12-50. View

16.

Jhawer M, Goel S, Wilson A, Montagna C, Ling Y, Byun D . PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008; 68(6):1953-61. PMC: 3972216. DOI: 10.1158/0008-5472.CAN-07-5659. View

17.

Fassan M, Simbolo M, Bria E, Mafficini A, Pilotto S, Capelli P . High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer. 2013; 17(3):442-9. DOI: 10.1007/s10120-013-0315-1. View

18.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

19.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S . High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304(5670):554. DOI: 10.1126/science.1096502. View

20.

Oda K, Stokoe D, Taketani Y, McCormick F . High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005; 65(23):10669-73. DOI: 10.1158/0008-5472.CAN-05-2620. View